Introduction: Parkinson’s Disease (PD) is one of the most common age-related neurodegenerative
disorders which is marked with the loss of dopaminergic neurons. The present study
performed on the nose to brain delivery of selegiline hydrochloride loaded nano lipid carrier, suggests
that the nasal route is a good mean of targeting the drug directly into the brain.
Methods and Materials: Nanostructured lipid carriers were prepared by using hot homogenization.
Selegiline hydrochloride loaded NLCs and rotenone treatment were given at a dose of 10 mg/kg administered
from 14th day to 28th day. Behavioral parameters were determined at 7th, 14th, 21st and 28th
day. On the 28th day, animals were sacrificed for biochemical estimation.
Results: The optimized drug loaded NLC formulation has shown 93±5.25% entrapment efficiency
and 51.96% loading capacity. Optimized NLCs formulation has shown 70% release within 10 hours
and after that, the release of the drug is sustained up to 22 hours (97%). Pharmacological action of
the drug was found to restore the behavioral parameters in rotenone-induced rats.
Conclusion: Nano Lipid Carrier (NLCs) therapeutics has emerged as a prominent method for the
treatment of Parkinson’s Disease (PD) as it offers targeted delivery and enhances the therapeutic efficacy
of neurotherapeutics. It is concluded from the studies that, Selegiline HCl loaded nano lipid
carrier which was administered through nasal route has the potential to be used in the management
therapy of Parkinson’s disease.